BCR and immunoglobulin G4-related sclerosing disease: This review summarizes current evidence establishing BCR signaling as a central regulatory and therapeutic target in rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, IgG4-related disease, and ANCA-associated vasculitis.